Drug Profile
Fosifloxuridine nafalbenamide - Nucana BioMed
Alternative Names: 5-Fluorouracil ProTide - NuCana; FUDR-phosphoramidate; NUC 3373Latest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator Cardiff University
- Developer NuCana
- Class Amino acids; Antineoplastics; Fluorinated hydrocarbons; Naphthalenes; Pyrimidine nucleotides; Small molecules; Uracil nucleotides
- Mechanism of Action DNA synthesis inhibitors; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
- Phase I/II Solid tumours
- Phase I Non-small cell lung cancer
- No development reported Breast cancer
Most Recent Events
- 21 Mar 2024 NuCana BioMed completes a phase I/II trial in Colorectal cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater, Inoperable/Unresectable) in United Kingdom, USA and France (IV) (NCT03428958)
- 17 Oct 2023 Updated efficacy data from a phase I trial in solid tumours released by Nucana
- 11 Oct 2023 Efficacy and adverse events data from a phase I/II trial in Colorectal cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 ( AACR-NCI-EORTC-2023)